A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1

Olga C. Rodriguez, Edwin W. Lai, Sarada Vissapragada, Caroline Cromelin, Maral Avetian, Patricia Salinas, Hida Ramos, Bhaskar Kallakury, Mathew Casimiro, Michael P. Lisanti, Herbert B. Tanowitz, Karel Pacak, Robert I. Glazer, Maria Avantaggiati, Chris Albanese

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Loss of function at the Pten tumor-suppressor locus is a common genetic modification found in human prostate cancer. While recent in vivo and in vitro data support an important role of aberrant ErbB-2 signaling to clinically relevant prostate target genes, such as cyclin D1, the role of Pten in ErbB-2-induced prostate epithelial proliferation is not well understood. In the Pten-deficient prostate cancer cell line, LNCaP, restoration of Pten was able to inhibit ErbB-2- and heregulin-induced cell cycle progression, as well as cyclin D1 protein levels and promoter activity. Previously, we established that probasin-driven ErbB-2 transgenic mice presented with high-grade prostate intraepithelial neoplasia and increased nuclear cyclin D1 levels. We show that monoallelic loss of pten in the probasin-driven-ErbB-2 model resulted in increased nuclear cyclin D1 and proliferating cell nuclear antigen levels and decreased disease latency compared to either individual genetic model and, unlike the probasin-driven-ErbB-2 mice, progression to adenocarcinoma. Activated 3-phosphoinositide-dependent protein kinase-1 was observed during cancer initiation combined with the activation of p70S6K (phospho-T389) and inactivation of the 4E-binding protein-1 (phosphorylated on T37/46) and was primarily restricted to those cases of prostate cancer that had progressed to adenocarcinoma. Activation of mTOR was not seen. Our data demonstrates that Pten functions downstream of ErbB-2 to restrict prostate epithelial transformation by blocking full activation of the PDK1 signaling cascade.

Original languageEnglish (US)
Pages (from-to)2051-2060
Number of pages10
JournalAmerican Journal of Pathology
Volume174
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Cyclin D1
Prostate
Adenocarcinoma
Prostatic Neoplasms
Neoplasms
3-Phosphoinositide-Dependent Protein Kinases
Neuregulin-1
70-kDa Ribosomal Protein S6 Kinases
Genetic Models
Proliferating Cell Nuclear Antigen
Transgenic Mice
Cell Cycle
Carrier Proteins
Cell Line
Genes
probasin
Proteins

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. / Rodriguez, Olga C.; Lai, Edwin W.; Vissapragada, Sarada; Cromelin, Caroline; Avetian, Maral; Salinas, Patricia; Ramos, Hida; Kallakury, Bhaskar; Casimiro, Mathew; Lisanti, Michael P.; Tanowitz, Herbert B.; Pacak, Karel; Glazer, Robert I.; Avantaggiati, Maria; Albanese, Chris.

In: American Journal of Pathology, Vol. 174, No. 6, 06.2009, p. 2051-2060.

Research output: Contribution to journalArticle

Rodriguez, OC, Lai, EW, Vissapragada, S, Cromelin, C, Avetian, M, Salinas, P, Ramos, H, Kallakury, B, Casimiro, M, Lisanti, MP, Tanowitz, HB, Pacak, K, Glazer, RI, Avantaggiati, M & Albanese, C 2009, 'A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1', American Journal of Pathology, vol. 174, no. 6, pp. 2051-2060. https://doi.org/10.2353/ajpath.2009.080859
Rodriguez, Olga C. ; Lai, Edwin W. ; Vissapragada, Sarada ; Cromelin, Caroline ; Avetian, Maral ; Salinas, Patricia ; Ramos, Hida ; Kallakury, Bhaskar ; Casimiro, Mathew ; Lisanti, Michael P. ; Tanowitz, Herbert B. ; Pacak, Karel ; Glazer, Robert I. ; Avantaggiati, Maria ; Albanese, Chris. / A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. In: American Journal of Pathology. 2009 ; Vol. 174, No. 6. pp. 2051-2060.
@article{54d56354f33e4495ab9d6586c40d9631,
title = "A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1",
abstract = "Loss of function at the Pten tumor-suppressor locus is a common genetic modification found in human prostate cancer. While recent in vivo and in vitro data support an important role of aberrant ErbB-2 signaling to clinically relevant prostate target genes, such as cyclin D1, the role of Pten in ErbB-2-induced prostate epithelial proliferation is not well understood. In the Pten-deficient prostate cancer cell line, LNCaP, restoration of Pten was able to inhibit ErbB-2- and heregulin-induced cell cycle progression, as well as cyclin D1 protein levels and promoter activity. Previously, we established that probasin-driven ErbB-2 transgenic mice presented with high-grade prostate intraepithelial neoplasia and increased nuclear cyclin D1 levels. We show that monoallelic loss of pten in the probasin-driven-ErbB-2 model resulted in increased nuclear cyclin D1 and proliferating cell nuclear antigen levels and decreased disease latency compared to either individual genetic model and, unlike the probasin-driven-ErbB-2 mice, progression to adenocarcinoma. Activated 3-phosphoinositide-dependent protein kinase-1 was observed during cancer initiation combined with the activation of p70S6K (phospho-T389) and inactivation of the 4E-binding protein-1 (phosphorylated on T37/46) and was primarily restricted to those cases of prostate cancer that had progressed to adenocarcinoma. Activation of mTOR was not seen. Our data demonstrates that Pten functions downstream of ErbB-2 to restrict prostate epithelial transformation by blocking full activation of the PDK1 signaling cascade.",
author = "Rodriguez, {Olga C.} and Lai, {Edwin W.} and Sarada Vissapragada and Caroline Cromelin and Maral Avetian and Patricia Salinas and Hida Ramos and Bhaskar Kallakury and Mathew Casimiro and Lisanti, {Michael P.} and Tanowitz, {Herbert B.} and Karel Pacak and Glazer, {Robert I.} and Maria Avantaggiati and Chris Albanese",
year = "2009",
month = "6",
doi = "10.2353/ajpath.2009.080859",
language = "English (US)",
volume = "174",
pages = "2051--2060",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1

AU - Rodriguez, Olga C.

AU - Lai, Edwin W.

AU - Vissapragada, Sarada

AU - Cromelin, Caroline

AU - Avetian, Maral

AU - Salinas, Patricia

AU - Ramos, Hida

AU - Kallakury, Bhaskar

AU - Casimiro, Mathew

AU - Lisanti, Michael P.

AU - Tanowitz, Herbert B.

AU - Pacak, Karel

AU - Glazer, Robert I.

AU - Avantaggiati, Maria

AU - Albanese, Chris

PY - 2009/6

Y1 - 2009/6

N2 - Loss of function at the Pten tumor-suppressor locus is a common genetic modification found in human prostate cancer. While recent in vivo and in vitro data support an important role of aberrant ErbB-2 signaling to clinically relevant prostate target genes, such as cyclin D1, the role of Pten in ErbB-2-induced prostate epithelial proliferation is not well understood. In the Pten-deficient prostate cancer cell line, LNCaP, restoration of Pten was able to inhibit ErbB-2- and heregulin-induced cell cycle progression, as well as cyclin D1 protein levels and promoter activity. Previously, we established that probasin-driven ErbB-2 transgenic mice presented with high-grade prostate intraepithelial neoplasia and increased nuclear cyclin D1 levels. We show that monoallelic loss of pten in the probasin-driven-ErbB-2 model resulted in increased nuclear cyclin D1 and proliferating cell nuclear antigen levels and decreased disease latency compared to either individual genetic model and, unlike the probasin-driven-ErbB-2 mice, progression to adenocarcinoma. Activated 3-phosphoinositide-dependent protein kinase-1 was observed during cancer initiation combined with the activation of p70S6K (phospho-T389) and inactivation of the 4E-binding protein-1 (phosphorylated on T37/46) and was primarily restricted to those cases of prostate cancer that had progressed to adenocarcinoma. Activation of mTOR was not seen. Our data demonstrates that Pten functions downstream of ErbB-2 to restrict prostate epithelial transformation by blocking full activation of the PDK1 signaling cascade.

AB - Loss of function at the Pten tumor-suppressor locus is a common genetic modification found in human prostate cancer. While recent in vivo and in vitro data support an important role of aberrant ErbB-2 signaling to clinically relevant prostate target genes, such as cyclin D1, the role of Pten in ErbB-2-induced prostate epithelial proliferation is not well understood. In the Pten-deficient prostate cancer cell line, LNCaP, restoration of Pten was able to inhibit ErbB-2- and heregulin-induced cell cycle progression, as well as cyclin D1 protein levels and promoter activity. Previously, we established that probasin-driven ErbB-2 transgenic mice presented with high-grade prostate intraepithelial neoplasia and increased nuclear cyclin D1 levels. We show that monoallelic loss of pten in the probasin-driven-ErbB-2 model resulted in increased nuclear cyclin D1 and proliferating cell nuclear antigen levels and decreased disease latency compared to either individual genetic model and, unlike the probasin-driven-ErbB-2 mice, progression to adenocarcinoma. Activated 3-phosphoinositide-dependent protein kinase-1 was observed during cancer initiation combined with the activation of p70S6K (phospho-T389) and inactivation of the 4E-binding protein-1 (phosphorylated on T37/46) and was primarily restricted to those cases of prostate cancer that had progressed to adenocarcinoma. Activation of mTOR was not seen. Our data demonstrates that Pten functions downstream of ErbB-2 to restrict prostate epithelial transformation by blocking full activation of the PDK1 signaling cascade.

UR - http://www.scopus.com/inward/record.url?scp=67049157933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049157933&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2009.080859

DO - 10.2353/ajpath.2009.080859

M3 - Article

C2 - 19443706

AN - SCOPUS:67049157933

VL - 174

SP - 2051

EP - 2060

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -